advertisement

Topcon

Abstract #105760 Published in IGR 23-3

Therapeutic Gene Editing in Inherited Retinal Disorders

Ling J; Jenny LA; Zhou A; Tsang SH
Cold Spring Harbor perspectives in medicine 2023; 13:


Since the development of CRISPR/Cas9 gene editing in 2012, therapeutic editing research has produced several phase 1-2a trials. Here we provide an overview of the mechanisms and applications of various gene-editing technologies including adeno-associated virus vectors, lentiviruses, CRISPR/Cas9 systems, base and prime editing, antisense oligonucleotides, short-hairpin RNAs, Cas13, and adenosine deaminase acting on RNA for the treatment of various inherited retinal diseases (IRDs). We outline the various stages of clinical trials using these technologies and the impacts they have made in advancing the practice of medicine.

Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA.

Full article

Classification:

15 Miscellaneous



Issue 23-3

Change Issue


advertisement

Oculus